

MabSpace receives FDA Approval for MSB2311

27 February 2018 | News

MabSpace Biosciences Announces FDA Approval of IND for MSB2311, a Second Generation PD-L1 Antibody With pH Dependent Antigen Binding and Recycling Property



MabSpace is a global biotechnology company focused on discovering and developing innovative antibody therapeutics using its proprietary immune tolerance breaking technology.

PD-L1 is a key checkpoint protein employed by tumor cells to escape host immune surveillance. Multiple antibodies inhibiting PD-L1 have been approved by FDA for the treatment of various solid tumors.

MSB2311 is differentiated by its distinct binding epitope and unique pH dependent PD-L1 binding and recycling property.

MSB2311 is a human IgG1 with no FcR binding ability and thus has no ADCC-inducing activity.

MSB2311 has shown to be safe in non-human primate and efficacious in multiple mouse tumor models, and has exhibited robust CMC profile.

MabSpace has built a pipeline focused on immuno-oncology with MSB2311 as its first molecule entering into clinic. With a panel of pipeline antibody molecules targeting various pathways regulating tumor immune cycle, MSB2311 will also serve as a key backbone agent for combination approach.